Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06DET
|
|||
| Former ID |
DNC000164
|
|||
| Drug Name |
AE-3763
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Chronic obstructive pulmonary disease [ICD-11: CA22; ICD-10: J44, J44.9] | Discontinued in Phase 1 | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C23H34F3N5O7
|
|||
| Canonical SMILES |
CC(C)C(C(=O)C(F)(F)F)NC(=O)C1CCCN1C(=O)C(C(C)C)NC(=O)CN2CCN(C2=O)CC(=O)O
|
|||
| InChI |
1S/C23H34F3N5O7/c1-12(2)17(19(35)23(24,25)26)28-20(36)14-6-5-7-31(14)21(37)18(13(3)4)27-15(32)10-29-8-9-30(22(29)38)11-16(33)34/h12-14,17-18H,5-11H2,1-4H3,(H,27,32)(H,28,36)(H,33,34)/t14-,17-,18-/m0/s1
|
|||
| InChIKey |
DHQQXRRWRZFGDW-WBAXXEDZSA-N
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| SuperDrug ATC ID |
R03DC04
|
|||
| SuperDrug CAS ID |
cas=050847115
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Neutrophil elastase (NE) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Transcriptional misregulation in cancer | |||
| Systemic lupus erythematosus | ||||
| Pathway Interaction Database | Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling | |||
| C-MYB transcription factor network | ||||
| Reactome | Collagen degradation | |||
| Degradation of the extracellular matrix | ||||
| Activation of Matrix Metalloproteinases | ||||
| WikiPathways | Hair Follicle Development: Cytodifferentiation (Part 3 of 3) | |||
| Human Complement System | ||||
| Degradation of collagen | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015539) | |||
| REF 2 | Neutrophil elastase inhibitors as treatment for COPD. Expert Opin Investig Drugs. 2002 Jul;11(7):965-80. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.